Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SEATTLE, Sept. 20, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017, at 9:45 a.m. EDT / 6:45 a.m. PDT in New York City.
A live audio webcast of the presentation will be available through the “Events & Presentations” page of the “News & Events” section of Cascadian Therapeutics’ website at cascadianrx.com. An archived edition of the session will be available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
[email protected]
